Presentations At AHA Expand On Clinical Utility Of DeCODE’s DNA-based Tests

Several presentations by deCODE genetics (Nasdaq:DCGN) scientists and independent researchers at the American Heart Association Scientific Sessions 2008 being held at the New Orleans Convention Center from November 8 to12 are expected to expand upon the clinical utility of evaluating individual risk of heart attack, or atrial fibrillation and stroke, respectively, by measuring the genetic markers that are the basis of the deCODE MI? and deCODE AF? tests.

More: continued here

Filed under: Cardiovascular on November 11th, 2008